Back to Directory
Somapacitan
Performance & EnduranceLong-acting growth hormone with weekly dosing for growth hormone deficiency.
Key Benefits
- ✓Once-weekly GH therapy
- ✓Treats GH deficiency
- ✓Improved compliance
- ✓Long-acting formulation
- ✓Similar efficacy to daily GH
Dosing Information
Dosage Range
0.5-8 mg
Frequency
Once weekly
Typical Duration
Ongoing
Detailed Protocol
Administered via subcutaneous injection once weekly. Dose individualized and titrated based on IGF-1 levels. Prescription required for GH deficiency.
About Somapacitan
Somapacitan (Sogroya) is a reversible albumin-binding growth hormone derivative enabling once-weekly administration. FDA-approved for adult growth hormone deficiency. First weekly GH option.
Research Notes
FDA-approved in 2020 for adult GHD. First once-weekly GH product. Clinical trials showed non-inferiority to daily somatropin with improved convenience.
Potential Side Effects
- •Headache
- •Fatigue
- •Injection site reactions
- •Peripheral edema
- •Arthralgia
- •Similar to daily GH
Always consult with a healthcare professional before starting any peptide therapy.